Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2
Tanushree Dangi, Jacob Class, Nicole Palacio, et al.
Cell Reports (2021) Vol. 36, Iss. 10, pp. 109664-109664
Open Access | Times Cited: 132

Showing 1-25 of 132 citing articles:

SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines
Suresh Thakur, Shalitha Sasi, Sindhu Gopinathan Pillai, et al.
Frontiers in Medicine (2022) Vol. 9
Open Access | Times Cited: 133
Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity
Shang Jui Tsai, Nadia A. Atai, Mafalda Cacciottolo, et al.
Journal of Biological Chemistry (2021) Vol. 297, Iss. 5, pp. 101266-101266
Open Access | Times Cited: 109
Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models
Renee L. Hajnik, Jessica A. Plante, Yuejin Liang, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 662
Open Access | Times Cited: 94
Cell surface SARS-CoV-2 nucleocapsid protein modulates innate and adaptive immunity
Alberto Domingo López-Muñoz, Ivan Košík, Jaroslav Hollý, et al.
Science Advances (2022) Vol. 8, Iss. 31
Open Access | Times Cited: 88
The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2
Grigoris D. Amoutzias, Marios Nikolaidis, Eleni Tryfonopoulou, et al.
Viruses (2022) Vol. 14, Iss. 1, pp. 78-78
Open Access | Times Cited: 82
An Update on Anti-COVID-19 Vaccines and the Challenges to Protect Against New SARS-CoV-2 Variants
Fábio Mambelli, Ana Carolina V. S. C. de Araujo, Jéssica Pires Farias, et al.
Pathogens (2025) Vol. 14, Iss. 1, pp. 23-23
Open Access | Times Cited: 1
Comparison of antibody and T cell responses elicited by BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) vaccines against SARS-CoV-2 in healthy adult humans
István Vályi‐Nagy, Zsolt Matula, Márton Gönczi, et al.
GeroScience (2021) Vol. 43, Iss. 5, pp. 2321-2331
Open Access | Times Cited: 75
T cell immunity to SARS-CoV-2
Julia Niessl, Takuya Sekine, Marcus Buggert
Seminars in Immunology (2021) Vol. 55, pp. 101505-101505
Open Access | Times Cited: 71
Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody
Tanushree Dangi, Sarah Sanchez, Jacob Class, et al.
Journal of Clinical Investigation (2022) Vol. 132, Iss. 23
Open Access | Times Cited: 54
Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates
Flavia Chiuppesi, Vu H. Nguyen, Yoonsuh Park, et al.
npj Vaccines (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 50
A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection
Nanda Kishore Routhu, Sailaja Gangadhara, Lilin Lai, et al.
Science Immunology (2022) Vol. 7, Iss. 72
Open Access | Times Cited: 37
Pre-existing immunity modulates responses to mRNA boosters
Tanushree Dangi, Sarah Sanchez, Min Han Lew, et al.
Cell Reports (2023) Vol. 42, Iss. 3, pp. 112167-112167
Open Access | Times Cited: 34
Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate
Javier Villadiego, Juan García‐Arriaza, Reposo Ramírez‐Lorca, et al.
Nature Neuroscience (2023) Vol. 26, Iss. 2, pp. 226-238
Open Access | Times Cited: 29
Exosome-Based Multivalent Vaccine: Achieving Potent Immunization, Broadened Reactivity, and Strong T-Cell Responses with Nanograms of Proteins
Mafalda Cacciottolo, Justin B Nice, Yujia Li, et al.
Microbiology Spectrum (2023) Vol. 11, Iss. 3
Open Access | Times Cited: 23
OVX033, a nucleocapsid-based vaccine candidate, provides broad-spectrum protection against SARS-CoV-2 variants in a hamster challenge model
Charlotte Primard, Élodie Monchâtre-Leroy, Judith del Campo, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 22
Cross-protective immunity following coronavirus vaccination and coronavirus infection
Tanushree Dangi, Nicole Palacio, Sarah Sanchez, et al.
Journal of Clinical Investigation (2021) Vol. 131, Iss. 24
Open Access | Times Cited: 52
The role of SARS-CoV-2 nucleocapsid protein in antiviral immunity and vaccine development
Haiyun Yu, Fei Guan, Heather Miller, et al.
Emerging Microbes & Infections (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 29
Cross-reactive immunity against SARS-CoV-2 N protein in Central and West Africa precedes the COVID-19 pandemic
Jannie Pedersen, Ismaël Hervé Koumakpayi, Giorgi Babuadze, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 28
Neuro-PASC is characterized by enhanced CD4+ and diminished CD8+ T cell responses to SARS-CoV-2 Nucleocapsid protein
Lavanya Visvabharathy, Barbara A. Hanson, Zachary S. Orban, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 20
The role of SARS-CoV-2 N protein in diagnosis and vaccination in the context of emerging variants: present status and prospects
Wanchen Song, Zhongbiao Fang, Feike Ma, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 16
Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants
Felix Wussow, Mindy Kha, Tae Hyun Kim, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 15
The Nucleocapsid Protein of SARS-CoV-2, Combined with ODN-39M, Is a Potential Component for an Intranasal Bivalent Vaccine with Broader Functionality
Yadira Lobaina, Rong Chen, Edith Suzarte, et al.
Viruses (2024) Vol. 16, Iss. 3, pp. 418-418
Open Access | Times Cited: 6
Molecular characterization of SARS-CoV-2 nucleocapsid protein
Yanping Huang, Junkai Chen, Siwei Chen, et al.
Frontiers in Cellular and Infection Microbiology (2024) Vol. 14
Open Access | Times Cited: 6
Construction and immune effect evaluation of the S protein heptad repeat-based nanoparticle vaccine against porcine epidemic diarrhea virus
Dan Yang, Xinglin Wang, Xu Yang, et al.
Virology (2024) Vol. 596, pp. 110113-110113
Closed Access | Times Cited: 5
The Key to Increase Immunogenicity of Next-Generation COVID-19 Vaccines Lies in the Inclusion of the SARS-CoV-2 Nucleocapsid Protein
Noe Juvenal Mendoza-Ramírez, Julio García‐Cordero, Gaurav Shrivastava, et al.
Journal of Immunology Research (2024) Vol. 2024, pp. 1-18
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top